Kalohexis Inc.

Kalohexis Inc. is a clinical-stage biotechnology company dedicated to advancing the treatment of metabolic diseases. Headquartered in Northbrook, Illinois, the company's mission is to shape the next era of metabolic disease care by leveraging the melanocortin system, the body's natural regulator of metabolic homeostasis.

Kalohexis focuses on developing proprietary peptide therapeutics designed to safely and effectively target central melanocortin-3 and melanocortin-4 receptors (MC3R/MC4R). Its pipeline includes 710GO, an oral dual MC3R/MC4R agonist currently in Phase 1 clinical trials for general obesity, and mifomelatide, a dual MC3R/MC4R antagonist in Phase 2 for cancer cachexia. The company aims to address a range of metabolic disorders, including obesity and cachexia, with potential applications in type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and other conditions.

Kalohexis was launched in March 2026 as a spin-out from Endevica Bio, with the leadership team transitioning to the new entity. Recent developments include the dosing of the first patients in the Phase 1 clinical trial for 710GO in May 2026 and presentations at ENDO 2026 in June 2026, highlighting the potential of its dual MC3R/MC4R activation mechanism for durable weight loss. The company's approach seeks to establish a new metabolic set point, differentiating it from existing therapies.